Search clinical trials for: Trivalent influenza vaccine

Total 11176 results

Sinovac Biotech Co., Ltd

Recruiting

A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Butantan Institute
Fundação Butantan

Recruiting

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Influenza, Human

Brazil
Sinovac Biotech Co., Ltd

Recruiting

A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Mahidol University
Ministry of Health, Thailand; Bhumirajanagarindra Kidney Institute, Thailand

Recruiting

Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients (Enhance)

ESRD | Influenza Vaccine | Seroprotection

Thailand
Mahidol University
The Government Pharmaceutical Organization

Recruiting

Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly

Influenza

Thailand
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
Jennifer Woyach
Pharmacyclics LLC.

Active, not recruiting

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Radboud University Medical Center
Amgen

Completed

Rivaroxaban Sotorasib Interaction Study (ROSIE)

Drug Drug Interaction Study

Netherlands
Vanderbilt-Ingram Cancer Center

Active, not recruiting

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

Hematopoietic Cell Transplantation

United States
Emory University
National Cancer Institute (NCI); Sanofi; National Institutes of Health (NIH)

Completed

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Plasma Cell Neoplasm

United States
Butantan Institute

Completed

Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine

Influenza

Brazil
Universitas Padjadjaran
Universiti Sains Malaysia; Biofarma

Completed

Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)

Diabetes Mellitus | Chronic Kidney Diseases | Vaccine Reaction | Influenza

Indonesia
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

Influenza | Malignant Neoplasm | Hematopoietic Cell Transplantation Recipient

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (SLVP033)

Hepatitis A | Influenza | Healthy Adults | Typhoid

United States
Shanghai Institute Of Biological Products

Completed

A Clinical Trial of A Quadrivalent Influenza Vaccine

Influenza

China
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

Influenza

China
Il-Yang Pharm. Co., Ltd.

Completed

Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'

Influenza
Roswell Park Cancer Institute

Completed

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Influence of Chronic CMV Infection on Influenza Vaccine Responses (SLVP025)

Influenza | Cytomegalovirus Infections

United States
University of British Columbia
Ministry of Health, British Columbia

Completed

Evaluation of Therapeutic Initiative's Cystitis Portrait and Therapeutics Letter

Quality Improvement | Clinical Audit

Canada
Seqirus
Novartis Vaccines

Completed

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Influenza Virus

United States, Canada, Finland, Italy, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
Novavax

Completed

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

Influenza

United States
Seqirus

Completed

Flucelvax (TIVc or QIVc) Pregnancy Registry

Pregnancy | Influenza, Human | Birth Defect

United States
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Influenza

United States
Inova Health Care Services

Completed

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

Influenza, Human | Transplantation Infection

United States
Sanofi

Completed

Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years

Influenza | Flu

China
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Influenza

United States
Jiangsu Province Centers for Disease Control and...

Completed

Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

COVID-19

China
Sanofi
Protein Sciences Corporation

Completed

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; National Heart, Lung, and Blood... and other collaborators

Completed

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)

Myocardial Infarction | Heart Failure

United States, Canada, Puerto Rico
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

Glioma | Astrocytoma | Oligodendroglioma

United States
MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
MedImmune LLC

Completed

Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age

Influenza

United States, United Kingdom, Belgium, Czechia, Hong Kong, Ireland, Korea, Republic of, Taiwan
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

Influenza

United States
University of Maryland, Baltimore
D'Antonio Consultants International, Inc.

Completed

Safety Study of Seasonal Influenza Vaccine by Jet Injection

Healthy Adults

United States
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
Mahidol University
World Health Organization; The Government Pharmaceutical Organization

Completed

Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults

Influenza

Thailand
Mahidol University
World Health Organization; The Government Pharmaceutical Organization

Completed

Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults

Influenza
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Cholecalciferol and Flu Vaccine in Treating Healthy Participants

Healthy, no Evidence of Disease

United States
Mahidol University
Ministry of Health, Thailand; Bhumirajanagarindra Kidney Institute, Thailand

Completed

Immune Response to Influenza Vaccine in ESRD Patients

Immunology | Nephrology
University of Maryland, Baltimore
Bill and Melinda Gates Foundation

Completed

Maternal Flu Vaccine Trial in Bamako, Mali

Influenza

Mali
Novartis Vaccines

Completed

Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)

Influenza

Lithuania
Novartis Vaccines

Completed

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

Influenza

Finland, United States, Poland
Institute of Vaccines and Medical Biologicals,...
Quintiles, Inc.; PATH; World Health Organization; Pasteur Institute, Ho Chi Minh...

Completed

Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3 (IVACFLUS-0203)

Influenza, Human

Vietnam
PharmaJet, Inc.

Completed

Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe

Influenza Prophylaxis

United States
Novartis Vaccines

Completed

A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

Influenza

Korea, Republic of

Search clinical trials for: Trivalent influenza vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations